DSGN — Design Therapeutics Income Statement
0.000.00%
- $229.93m
- -$40.75m
- 59
- 37
- 69
- 55
Annual income statement for Design Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.834 | 0.226 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 2.74 | 8.56 | 35.8 | 67.6 | 78.2 |
Operating Profit | -1.91 | -8.33 | -35.8 | -67.6 | -78.2 |
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2.05 | -8.28 | -35.5 | -63.3 | -66.9 |
Net Income After Taxes | -2.05 | -8.28 | -35.5 | -63.3 | -66.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -2.05 | -8.28 | -35.5 | -63.3 | -66.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.05 | -8.28 | -35.5 | -63.3 | -66.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.038 | -0.154 | -0.774 | -1.14 | -1.19 |
Dividends per Share |